Christelle d'Engremont

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Background In advanced pancreatic ductal adenocarcinoma (aPDAC), there is no consensual strategy for second-line chemotherapy (L2). Better discrimination of overall survival (OS) may help clinical decision-making. We aimed to predict OS from the beginning of L2 and to assess the benefit from chemotherapy among the identified risk groups. Methods Analyses(More)
  • 1